



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/47, 16/18, C12Q 1/68, A61K 38/17	A3	(11) International Publication Number: WO 99/57144 (43) International Publication Date: 11 November 1999 (11.11.99)																					
<p>(21) International Application Number: PCT/US99/09935</p> <p>(22) International Filing Date: 4 May 1999 (04.05.99)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>60/084,254</td> <td>5 May 1998 (05.05.98)</td> <td>US</td> </tr> <tr> <td>60/095,827</td> <td>7 August 1998 (07.08.98)</td> <td>US</td> </tr> <tr> <td>60/102,745</td> <td>2 October 1998 (02.10.98)</td> <td>US</td> </tr> </table> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</p> <table border="0"> <tr> <td>US</td> <td>60/084,254 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>5 May 1998 (05.05.98)</td> </tr> <tr> <td>US</td> <td>60/095,827 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>7 August 1998 (07.08.98)</td> </tr> <tr> <td>US</td> <td>60/102,745 (CIP)</td> </tr> <tr> <td>Filed on</td> <td>2 October 1998 (02.10.98)</td> </tr> </table> <p>(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View,</p>		60/084,254	5 May 1998 (05.05.98)	US	60/095,827	7 August 1998 (07.08.98)	US	60/102,745	2 October 1998 (02.10.98)	US	US	60/084,254 (CIP)	Filed on	5 May 1998 (05.05.98)	US	60/095,827 (CIP)	Filed on	7 August 1998 (07.08.98)	US	60/102,745 (CIP)	Filed on	2 October 1998 (02.10.98)	<p>CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). REDDY, Roopa [IN/US]; 1233 W. McKinley Drive, Sunnyvale, CA 94086 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). GERSTIN, Edward, H. [US/US]; 1408 38th Avenue, San Francisco, CA 94122 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94547 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US).</p> <p>(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p> <p>(88) Date of publication of the international search report: 6 April 2000 (06.04.00)</p>
60/084,254	5 May 1998 (05.05.98)	US																					
60/095,827	7 August 1998 (07.08.98)	US																					
60/102,745	2 October 1998 (02.10.98)	US																					
US	60/084,254 (CIP)																						
Filed on	5 May 1998 (05.05.98)																						
US	60/095,827 (CIP)																						
Filed on	7 August 1998 (07.08.98)																						
US	60/102,745 (CIP)																						
Filed on	2 October 1998 (02.10.98)																						
<p>(54) Title: HUMAN TRANSCRIPTIONAL REGULATOR MOLECULES</p>																							
<p>(57) Abstract</p> <p>The invention provides human transcriptional regulator molecules (HTRM) and polynucleotides which identify and encode HTRM. The invention also provides expression vectors, host cells, antibodies, agonists and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of HTRM.</p>																							

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/09935

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/12 C07K14/47 C07K16/18 C12Q1/68 A61K38/17		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HILLIER ET AL.: "WashU-NCI human EST Project" EMBL ACCESSION NO AA190560, 21 January 1997 (1997-01-21), XP002114035 the whole document ---	3-13
A	US 5 739 010 A (SHAH PURVI ET AL) 14 April 1998 (1998-04-14) column 30, line 24 -column 32, line 45 column 1, line 28 -column 2, line 23 ---	1-20
A	FREIMAN ET AL: "Viral mimicry: common mode of association with HCF by VP16 and the cellular protein LZIP" GENES AND DEVELOPMENT, vol. 11, December 1997 (1997-12), pages 3122-3127, XP002114036 figures 1,4 -----	1-20
<input type="checkbox"/> Further documents are listed in the continuation of box C.		
<input checked="" type="checkbox"/> Patent family members are listed in annex.		
° Special categories of cited documents :		
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search 3 September 1999		Date of mailing of the international search report 17. 12. 99
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer van Klompenburg, W

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 09935

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 19 and 20
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:

See FURTHER INFORMATION Sheet PCT/ISA/210
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

See additional sheet, Invention 1.

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

The subject-matter of claims 17 and 18 and of claim 20 in so far as it relates to antagonists is insufficiently characterized. A meaningful and complete search could therefore not be performed for said claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-20 partially

A substantially purified polypeptide according to SEQ ID NO 1 or a polypeptide with at least 90% identity or a fragment thereof. Methods for producing said polypeptide. Antibodies, antagonists and agonists of the said polypeptide. Methods of treatment using said polypeptides or antagonists.

An isolated polynucleotide encoding said polypeptide or an isolated polynucleotide with 70% identity to such a polynucleotide or a polynucleotide according to SEQ ID NO 66 and fragments of said polynucleotides.

Methods for detecting said polynucleotides.

Expression vectors comprising said polynucleotides and host cells comprising said expression vectors.

Inventions 2 to 65, claims: 1-20 partially

idem for SEQ ID NO 2-65 and the corresponding nucleotide sequences from SEQ ID NO 67-130.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/09935

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5739010 A	14-04-1998	NONE	